{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:19:29Z","timestamp":1768979969686,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Belgian Agency for Innovation by Science and Technology","award":["130691"],"award-info":[{"award-number":["130691"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejphar.2018.05.026","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T16:49:24Z","timestamp":1526662164000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction"],"prefix":"10.1016","volume":"832","author":[{"given":"Bianca","family":"Hemmeryckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"Lox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Trenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Vreeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua Rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Roger","family":"Lijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.05.026_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0002-9149(93)91118-2","article-title":"Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death","volume":"72","author":"Buja","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0140-6736(92)91740-Y","article-title":"Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide","volume":"340","author":"Buss","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.05.026_bib3","first-page":"155","article-title":"Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients","volume":"32","author":"Conard","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejphar.2018.05.026_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0735-1097(87)80096-7","article-title":"Influence of left ventricular dysfunction on flecainide therapy","volume":"9","author":"de Paolo","year":"1987","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.05.026_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.300.1.64","article-title":"Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation","volume":"300","author":"Eckardt","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.05.026_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/FJC.0000000000000287","article-title":"Pharmacological effects of cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.0\u2009T cardiac magnetic resonance imaging and histopathology","volume":"66","author":"Feng","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib8","doi-asserted-by":"crossref","unstructured":"Feng, Y., Hemmeryckx, B., Frederix, L., Lox, M., Wu, J., Heggermont, W., Lu, H.R., Gallacher, D., Oyen, R., Lijnen, H.R., Ni, Y., 2018. Monitoring Reperfused Myocardial Infarction with Delayed Left Ventricular Systolic Dysfunction in Rabbits by Longitudinal Imaging. (Unpublished results).","DOI":"10.21037\/qims.2018.09.05"},{"key":"10.1016\/j.ejphar.2018.05.026_bib9","first-page":"104","article-title":"Effect of flecainide acetate on reperfusion- and barium-induced ventricular tachyarrhythmias in the isolated perfused rat heart","volume":"308","author":"Ferrara","year":"1990","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejphar.2018.05.026_bib10","first-page":"351","article-title":"Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients","volume":"45","author":"Frandsen","year":"1990","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/eurjhf\/hfr107","article-title":"A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure","volume":"13","author":"Frommeyer","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2018.05.026_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.109.894725","article-title":"Drug-induced Arrhythmia","volume":"122","author":"Heist","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.05.026_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vascn.2010.04.010","article-title":"Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit","volume":"63","author":"Jacobson","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejphar.2018.05.026_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(85)90413-2","article-title":"Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease","volume":"109","author":"Josephson","year":"1985","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2018.05.026_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00399-013-0260-z","article-title":"The ECG in cardiovascular-relevant animal models of electrophysiology","volume":"24","author":"Kaese","year":"2013","journal-title":"Herzschrittmacher. Elektrophysiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/toxsci\/kfl025","article-title":"Use of a failing rabbit heart as a model to predict torsadogenicity","volume":"93","author":"Kijtawornrat","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejphar.2018.05.026_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.2011.01255.x","article-title":"How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?","volume":"163","author":"Laverty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00005344-198913040-00005","article-title":"Effects of flecainide on occlusion and reperfusion arrhythmias in dogs","volume":"13","author":"Lederman","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oxfordjournals.eurheartj.a061918","article-title":"Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy","volume":"6","author":"Legrand","year":"1985","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2018.05.026_bib20","doi-asserted-by":"crossref","first-page":"1418.e1","DOI":"10.1016\/j.ajem.2013.04.025","article-title":"Irreversible third-degree heart block and pacemaker implant in a case of flecainide toxicity","volume":"31","author":"Lloyd","year":"2013","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ejphar.2018.05.026_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.vascn.2016.06.006","article-title":"Assessment of drug-induced proarrhythmia: the importance of study design in the rabbit left ventricular wedge model","volume":"81","author":"Lu","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejphar.2018.05.026_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1476-5381.2010.00646.x","article-title":"Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers","volume":"160","author":"Lu","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vascn.2003.10.003","article-title":"QT and JT dispersion in the drug-induced long QT syndrome in anaesthetized rabbits is accurately detected by a three-lead surface ECG measurement","volume":"49","author":"Lu","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejphar.2018.05.026_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bjp.2008.191","article-title":"Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines","volume":"154","author":"Lu","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1540-8167.2006.00420.x","article-title":"Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit purkinje fibers: importance of beat-to-beat instability of the repolarization","volume":"17","author":"Lu","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.vascn.2013.01.003","article-title":"A new biomarker\u2013index of cardiac electrophysiological balance (iCEB)\u2013plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs)","volume":"68","author":"Lu","year":"2013","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejphar.2018.05.026_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.102.037911","article-title":"Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes","volume":"303","author":"Milberg","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.05.026_bib28","doi-asserted-by":"crossref","first-page":"89B","DOI":"10.1016\/0002-9149(84)90509-5","article-title":"Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram","volume":"53","author":"Morganroth","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/anec.12309","article-title":"Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a new biomarker for the identification of patients at increased Arrhythmic risk","volume":"21","author":"Robyns","year":"2016","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.ejphar.2018.05.026_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJM198607033150106","article-title":"Drug therapy. Flecainide","volume":"315","author":"Roden","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.05.026_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1378\/chest.103.4.1068","article-title":"Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function","volume":"103","author":"Santinelli","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2018.05.026_bib32","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.05.026_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0735-1097(03)00713-7","article-title":"Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance","volume":"42","author":"Yan","year":"2003","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918302917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918302917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T22:47:08Z","timestamp":1561070828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918302917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"alternative-id":["S0014299918302917"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.05.026","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}